They can’t keep getting away with this…
Just so we're clear.. the company famous for denying you care just had a banger quarter doing exactly that. Bigly.
In short, UnitedHealth put on an absolute clinic of a Q1 earnings from both sides as EPS adjusted came in at $7.23 against the $6.57 analysts penciled in. Revenue also had shorts throwing up in their mouths a bit as revenue mooned $111.72B in revenue against the $109.57B consensus. Naturally, investors liked what they saw and yeeted the stock 8% in morning trading. Oh, and management raised the 2026 adjusted EPS outlook to north of $18.25 (up from $17.75) and held the full-year revenue guide above $439B.
Meanwhile, other big pharma deniers insurers be like: “Save some money printing for the rest of us…”
That said, the real banger came from the medical benefit ratio. Which, friendly reminder, is the percentage of premiums paid out in actual medical care. Q1 came in at 83.9%, versus the 85.5% analysts were modeling and the 84.8% from a year ago. Translation: they collected more, paid out less. Analysts cheered. The patients whose premiums funded the beat… had different thoughts. Probably.
Stephen Hemsley, the man they dragged out of retirement last May to clean up the mess he arguably helped build during his original 2006-2017 run, is clearly cooking again. The turnaround playbook reads like a Fix-a-Fortune-50 checklist: shrink the membership base, dump the Optum UK business, pour money into AI, streamline access to care, and (this is my favorite) "increase transparency." You know, because 18 months of Change Healthcare breaches, DOJ probes, and a brand identity crisis be d*mned.
Also fighting the "good" fight: the administration recently finalized a 2027 Medicare Advantage payment rate bump that came in WAY fatter than originally proposed, handing the denials machine a fresh pay raise. F around and find out, indeed. The only dose of reality of the morning came in on the GLP-1 front. Insurers had until Monday to tell CMS whether they'd opt into Donny Ozempic's Medicare obesity drug coverage program. UNH… did not commit.
"We'd like to find a path, yes, there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure," said Bobby Hunter, the head of government programs, during the earnings call. Translation: "Cover Ozempic for 67 million Medicare eligibles at $245 a pop? We'll get back to you." Which, fair. The entire Q1 beat you just read about was literally built on the opposite strategy.
So where does that leave us? A stock still 50% off its highs, a CEO pulled out of retirement to stage a comeback, a DOJ probe lurking in the background, and a business that has once again discovered "managing medical costs" is a remarkably profitable strategy when you happen to own the claim-approval process.
In other words, business is booming at America's most hated insurance company… and somehow, I'm being told that's the bull case. Place your bets accordingly, friends. Until next time…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
